Mepsevii (Vestronidase alfa-vjbk)
- Medicine Name: Mepsevii
- Generic Name: Vestronidase alfa-vjbk
- Dosage Form & Strength: Injection: 10 mg/5 mL (2 mg/mL) in a single-dose vial
- Manufactured By: Ultragenyx Pharmaceutical Inc.
Mepsevii is a recombinant human lysosomal beta glucuronidase used to treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome.
Limitations of Use: The effect of medication Mepsevii on the central nervous system manifestations of MPS VII has not been determined.
Recommended Dosage: Mepsevii should be administered under the proper supervision of a health specialist with the capability to manage anaphylaxis. Premedication is required 30-60 minutes just before start of the infusion.
The recommended dosage of Mepsevii injection is 4 mg per kg (4 mg/kg) administered by intravenous infusion every 14 days (two weeks).
Administer the infusion over approximately 4 hours. In the first hour of infusion, infuse 2.5% of the total volume. After the first hour, the rate can be increased to infuse the remainder of the volume over 3 hours as tolerated.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.